Cargando…
Vitrectomy for macular edema due to retinal vein occlusion
Purpose: To determine the long-term outcomes of vitrectomy for the macular edema associated with a retinal vein occlusion (RVO). Methods: This was a retrospective, consecutive, interventional case series. The intraoperative procedures included internal limiting membrane peeling, arteriovenous sheath...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580136/ https://www.ncbi.nlm.nih.gov/pubmed/31354231 http://dx.doi.org/10.2147/OPTH.S203212 |
_version_ | 1783427977994829824 |
---|---|
author | Kumagai, Kazuyuki Ogino, Nobuchika Fukami, Marie Furukawa, Mariko |
author_facet | Kumagai, Kazuyuki Ogino, Nobuchika Fukami, Marie Furukawa, Mariko |
author_sort | Kumagai, Kazuyuki |
collection | PubMed |
description | Purpose: To determine the long-term outcomes of vitrectomy for the macular edema associated with a retinal vein occlusion (RVO). Methods: This was a retrospective, consecutive, interventional case series. The intraoperative procedures included internal limiting membrane peeling, arteriovenous sheathotomy, radial optic neurotomy, and intravitreal triamcinolone acetonide injection at the end of the surgery. The main outcome was the best-corrected visual acuity (BCVA). Results: Eight hundred and fifty-four eyes of 854 patients were studied. The eyes consisted of 602 with branch RVO (BRVO), 74 with hemi-central RVO (hemi-CRVO), 87 with nonischemic central retinal vein occlusion (CRVO), and 91 with ischemic CRVO. The mean follow-up period was 68.6 months with a range of 12 to 262 months. The mean BCVA was significantly improved at the final visit (P<0.0001 to 0.0016). The final BCVA improved in 74.4% of the BRVO eyes, in 58.1% of the hemi-CRVO eyes, in 57.4% of the nonischemic CRVO eyes, and in 51.6% of the ischemic CRVO eyes. Multiple regression analysis showed there was no significant relationship between the intraoperative combined procedures and the final BCVA. Conclusions: The results indicate that the type of RVO is significantly associated with the final BCVA, and vitrectomy is a treatment option to improve and maintain BCVA for a long term. |
format | Online Article Text |
id | pubmed-6580136 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-65801362019-07-26 Vitrectomy for macular edema due to retinal vein occlusion Kumagai, Kazuyuki Ogino, Nobuchika Fukami, Marie Furukawa, Mariko Clin Ophthalmol Original Research Purpose: To determine the long-term outcomes of vitrectomy for the macular edema associated with a retinal vein occlusion (RVO). Methods: This was a retrospective, consecutive, interventional case series. The intraoperative procedures included internal limiting membrane peeling, arteriovenous sheathotomy, radial optic neurotomy, and intravitreal triamcinolone acetonide injection at the end of the surgery. The main outcome was the best-corrected visual acuity (BCVA). Results: Eight hundred and fifty-four eyes of 854 patients were studied. The eyes consisted of 602 with branch RVO (BRVO), 74 with hemi-central RVO (hemi-CRVO), 87 with nonischemic central retinal vein occlusion (CRVO), and 91 with ischemic CRVO. The mean follow-up period was 68.6 months with a range of 12 to 262 months. The mean BCVA was significantly improved at the final visit (P<0.0001 to 0.0016). The final BCVA improved in 74.4% of the BRVO eyes, in 58.1% of the hemi-CRVO eyes, in 57.4% of the nonischemic CRVO eyes, and in 51.6% of the ischemic CRVO eyes. Multiple regression analysis showed there was no significant relationship between the intraoperative combined procedures and the final BCVA. Conclusions: The results indicate that the type of RVO is significantly associated with the final BCVA, and vitrectomy is a treatment option to improve and maintain BCVA for a long term. Dove 2019-06-13 /pmc/articles/PMC6580136/ /pubmed/31354231 http://dx.doi.org/10.2147/OPTH.S203212 Text en © 2019 Kumagai et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Kumagai, Kazuyuki Ogino, Nobuchika Fukami, Marie Furukawa, Mariko Vitrectomy for macular edema due to retinal vein occlusion |
title | Vitrectomy for macular edema due to retinal vein occlusion |
title_full | Vitrectomy for macular edema due to retinal vein occlusion |
title_fullStr | Vitrectomy for macular edema due to retinal vein occlusion |
title_full_unstemmed | Vitrectomy for macular edema due to retinal vein occlusion |
title_short | Vitrectomy for macular edema due to retinal vein occlusion |
title_sort | vitrectomy for macular edema due to retinal vein occlusion |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580136/ https://www.ncbi.nlm.nih.gov/pubmed/31354231 http://dx.doi.org/10.2147/OPTH.S203212 |
work_keys_str_mv | AT kumagaikazuyuki vitrectomyformacularedemaduetoretinalveinocclusion AT oginonobuchika vitrectomyformacularedemaduetoretinalveinocclusion AT fukamimarie vitrectomyformacularedemaduetoretinalveinocclusion AT furukawamariko vitrectomyformacularedemaduetoretinalveinocclusion |